Published in Br J Haematol on October 10, 2006
Body iron metabolism and pathophysiology of iron overload. Int J Hematol (2008) 1.59
Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease. Am J Hematol (2009) 1.48
Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. Am J Hematol (2009) 1.42
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
Cardiac iron across different transfusion-dependent diseases. Blood Rev (2008) 1.37
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica (2011) 1.23
Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med (2008) 1.07
Study on effectiveness of transfusion program in thalassemia major patients receiving multiple blood transfusions at a transfusion centre in Western India. Asian J Transfus Sci (2010) 1.04
Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol (2013) 1.03
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion (2008) 0.94
Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med (2011) 0.90
Frequency and risk factors of endocrine complications in Turkish children and adolescents with sickle cell anemia. Turk J Haematol (2013) 0.85
Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone (2008) 0.85
Physiopathology of Bone Modifications in β-Thalassemia. Anemia (2012) 0.83
Barriers to hematopoietic cell transplantation clinical trial participation of african american and black youth with sickle cell disease and their parents. J Pediatr Hematol Oncol (2013) 0.81
Hypogonadism in patients with sickle cell disease: central or peripheral? Acta Haematol (2012) 0.81
Beta thalassemia major in a developing country: epidemiological, clinical and evolutionary aspects. Mediterr J Hematol Infect Dis (2013) 0.80
Glucose metabolism in the Belgrade rat, a model of iron-loading anemia. Am J Physiol Gastrointest Liver Physiol (2013) 0.79
Thyroid function in major thalassemia patients: Is it related to height and chelation therapy? Caspian J Intern Med (2011) 0.78
Assessment of thyroid function in children aged 1-13 years with Beta-thalassemia major. Iran J Pediatr (2011) 0.78
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. Am J Hematol (2015) 0.76
Partial manual exchange reduces iron accumulation during chronic red cell transfusions for sickle cell disease. J Pediatr Hematol Oncol (2013) 0.76
Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome. PLoS One (2017) 0.75
Assessment Hepatomegaly and liver Enzymes in 100 Patients with beta Thalassemia Major in Mashhad, Iran. Iran J Ped Hematol Oncol (2012) 0.75
Selenium and Vitamin E as antioxidants in chronic hemolytic anemia: Are they deficient? A case-control study in a group of Egyptian children. J Adv Res (2015) 0.75
Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation. Pediatr Blood Cancer (2016) 0.75
Hormonal and echocardiographic abnormalities in adult patients with sickle-cell anemia in Bahrain. J Blood Med (2016) 0.75
Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia. Anemia (2015) 0.75
Does Sickle Cell Disease Protect Against Diabetes Mellitus?: Cross-sectional study. Sultan Qaboos Univ Med J (2015) 0.75
Organizing national responses for rare blood disorders: the Italian experience with sickle cell disease in childhood. Orphanet J Rare Dis (2013) 0.75
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA (2003) 8.18
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med (2014) 3.25
Heterogeneity of hemoglobin H disease in childhood. N Engl J Med (2011) 2.97
Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med (2003) 2.93
Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med (2010) 2.68
Factors associated with oxidative stress in human populations. Am J Epidemiol (2002) 2.13
Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood (2002) 2.02
Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol (2006) 1.99
Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation. Pediatr Crit Care Med (2007) 1.92
Smoking and exposure to environmental tobacco smoke decrease some plasma antioxidants and increase gamma-tocopherol in vivo after adjustment for dietary antioxidant intakes. Am J Clin Nutr (2003) 1.74
Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis (2011) 1.70
Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. Am J Clin Nutr (2009) 1.66
Quality of life in patients with thalassemia intermedia compared to thalassemia major. Ann N Y Acad Sci (2005) 1.59
Pernicious anemia with neuropsychiatric dysfunction in a patient with sickle cell anemia treated with folate supplementation. N Engl J Med (2003) 1.55
Blood product transfusions and clinical outcomes in pediatric patients with acute lung injury. Pediatr Crit Care Med (2009) 1.53
Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am (2006) 1.44
Managing sickle cell disease. BMJ (2003) 1.43
Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol (2005) 1.41
Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management. J Inherit Metab Dis (2013) 1.39
Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol (2007) 1.39
Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood (2011) 1.37
Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci (2005) 1.35
Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol (2006) 1.32
Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol (2006) 1.31
Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials (2011) 1.28
Pulmonary hypertension and NO in sickle cell. Blood (2010) 1.28
Intraindividual variability of plasma antioxidants, markers of oxidative stress, C-reactive protein, cotinine, and other biomarkers. Epidemiology (2006) 1.19
Relations of glycemic index and glycemic load with plasma oxidative stress markers. Am J Clin Nutr (2006) 1.18
Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood (2007) 1.17
Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis (2012) 1.16
The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level. Free Radic Biol Med (2008) 1.15
Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol (2003) 1.14
Bone mass density in adults with sickle cell disease. Br J Haematol (2007) 1.13
Adherence to study medication and visits: data from the BABY HUG trial. Pediatr Blood Cancer (2010) 1.12
An overview of evidence for a causal relationship between dietary availability of choline during development and cognitive function in offspring. Neurosci Biobehav Rev (2006) 1.12
Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit. Growth Horm IGF Res (2007) 1.11
Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol (2007) 1.08
Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc (2009) 1.08
Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr (2002) 1.07
Antioxidant supplementation decreases lipid peroxidation biomarker F(2)-isoprostanes in plasma of smokers. Cancer Epidemiol Biomarkers Prev (2002) 1.07
Guidelines for wrist posture based on carpal tunnel pressure thresholds. Hum Factors (2007) 1.03
Transient pseudohypoaldosteronism with hyponatremia-hyperkalemia in infant urinary tract infection. J Urol (2002) 1.01
Vitamin C treatment reduces elevated C-reactive protein. Free Radic Biol Med (2008) 1.01
Indoor air pollution in rural China: cooking fuels, stoves, and health status. Arch Environ Occup Health (2006) 1.01
Pulmonary hypertension in thalassemia. Ann N Y Acad Sci (2010) 1.01
Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol (2005) 1.00
Diet in midpuberty and sedentary activity in prepuberty predict peak bone mass. Am J Clin Nutr (2003) 1.00
Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). Br J Haematol (2012) 0.99
Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica (2013) 0.99
Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood (2012) 0.98
Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer (2006) 0.98
Perceived barriers to clinic appointments for adolescents with sickle cell disease. J Pediatr Hematol Oncol (2009) 0.97
Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program (2009) 0.95
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion (2008) 0.94
Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy (2006) 0.94
Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial. J Clin Endocrinol Metab (2008) 0.94
Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation. J Am Coll Nutr (2004) 0.94
Vitamin C supplementation decreases oxidative stress biomarker f2-isoprostanes in plasma of nonsmokers exposed to environmental tobacco smoke. Nutr Cancer (2003) 0.93
Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone (2011) 0.93
Management of type 2 diabetes mellitus associated with pituitary gigantism. Pituitary (2007) 0.93
Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. Br J Haematol (2005) 0.92
Associations between apolipoprotein E genotype and circulating F2-isoprostane levels in humans. Lipids (2005) 0.91
Orthopedic management of the extremities in patients with Morquio A syndrome. J Child Orthop (2014) 0.90
Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr Hematol Oncol (2007) 0.90
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson (2013) 0.89
Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis. J Pediatr Endocrinol Metab (2005) 0.89
Natural history of moderate aplastic anemia in children. Pediatr Blood Cancer (2004) 0.88
A pilot study of subcutaneous decitabine in β-thalassemia intermedia. Blood (2011) 0.88
Relationship of structural magnetic resonance imaging, magnetic resonance perfusion, and other disease factors to neuropsychological outcome in sickle cell disease. J Pediatr Psychol (2004) 0.88
Using acupuncture for acute pain in hospitalized children. Pediatr Crit Care Med (2009) 0.88
Vitamin C in plasma is inversely related to blood pressure and change in blood pressure during the previous year in young Black and White women. Nutr J (2008) 0.88
Fatal bone marrow embolism in a child with hemoglobin SE disease. Am J Hematol (2010) 0.87
Elevated insulin, proinsulin and insulin-like growth factor-binding protein-1 in liver disease. Growth Horm IGF Res (2003) 0.86
Oxandrolone for the treatment of bone marrow failure in Fanconi anemia. Pediatr Blood Cancer (2013) 0.86
Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone (2008) 0.85
Treatment of hepatitis C virus infection in thalassemia. Ann N Y Acad Sci (2005) 0.85
Deferiprone and hepatic fibrosis. Blood (2003) 0.85
Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis. Br J Ophthalmol (2010) 0.85
Isolated growth hormone deficiency. Pituitary (2007) 0.85
A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica (2013) 0.84
Learner-centered nutrition education improves folate intake and food-related behaviors in nonpregnant, low-income women of childbearing age. J Am Diet Assoc (2008) 0.84
A model for automated screening of thalassemia in hematology (math study). Lab Hematol (2007) 0.83
Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure. Orphanet J Rare Dis (2013) 0.83
Reproductive capacity in iron overloaded women with thalassemia major. Blood (2011) 0.83
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol (2012) 0.83
Longitudinal study of growth and adiposity in parous compared with nulligravid adolescents. Arch Pediatr Adolesc Med (2009) 0.83
Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr (2013) 0.82
Persistence of müllerian duct structures in a genetic male with distal monosomy 10q. Am J Med Genet A (2015) 0.82
Relationship between chronic transfusion therapy and body composition in subjects with thalassemia. J Pediatr (2010) 0.82
Near-Roadway Air Pollution and Coronary Heart Disease: Burden of Disease and Potential Impact of a Greenhouse Gas Reduction Strategy in Southern California. Environ Health Perspect (2015) 0.81